Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic spontaneous urticaria
Biotech
Novartis hands over $55M to license preclinical hives prospect
Novartis is paying Kyorin $55 million upfront for rights to a preclinical mast-cell-targeting candidate for chronic hives.
Darren Incorvaia
Mar 3, 2025 5:05pm
Third Harmonic halves headcount to take urticaria drug to ph. 2
Feb 11, 2025 7:58am
Allakos axes program, lays off 75% of staff after phase 1 flop
Jan 27, 2025 8:46am
Incyte's $750M buyout rocked by pause on key trial, asset cull
Nov 19, 2024 4:12am
Jasper dials up dose after hives responses come and go quickly
Oct 14, 2024 9:43am
Celldex anti-cKIT antibody reduces hives in another phase 2 test
Jul 30, 2024 5:50am
